● Recruiting

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Condition: Biliary Tract Cancers · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

PhasePhase 1

Planned participants25

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment in patients with advanced stage BTC.

This description comes directly from the study's public registry record.

Talk to the study team

Colleen Apostol, RN · 410-614-3644 · GIClinicalTrials@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

SKCCC Johns Hopkins Medical Institution

Baltimore, Maryland, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06564623